Radiotherapy (RT) plus the anti-EGFR monoclonal antibody Cetuximab (CTX) is an effective combination therapy for a subset of head and neck squamous cell carcinoma (HNSCC) patients. However, predictive markers of efficacy are missing, resulting in many patients treated with disappointing results and unnecessary toxicities. Here, we report that activation of EGFR upregulates miR-9 expression, which sustains the aggressiveness of HNSCC cells and protects from RT-induced cell death. Mechanistically, by targeting KLF5, miR-9 regulates the expression of the transcription factor Sp1 that, in turn, stimulates tumor growth and confers resistance to RT+CTX in vitro and in vivo. Intriguingly, high miR-9 levels have no effect on the sensitivity of HNSCC cells to cisplatin. In primary HNSCC, miR-9 expression correlated with Sp1 mRNA levels and high miR-9 expression predicted poor prognosis in patients treated with RT+CTX. Overall, we have discovered a new signaling axis linking EGFR activation to Sp1 expression that dictates the response to combination treatments in HNSCC. We propose that miR-9 may represent a valuable biomarker to select which HNSCC patients might benefit from RT+CTX therapy.

miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC / Citron, F.; Segatto, I.; Musco, L.; Pellarin, I.; Rampioni Vinciguerra, G. L.; Franchin, G.; Fanetti, G.; Micciche, F.; Giacomarra, V.; Lupato, V.; Favero, A.; Concina, I.; Srinivasan, S.; Avanzo, M.; Castiglioni, I.; Barzan, L.; Sulfaro, S.; Petrone, G.; Viale, A.; Draetta, G. F.; Vecchione, A.; Belletti, B.; Baldassarre, G.. - In: EMBO MOLECULAR MEDICINE. - ISSN 1757-4676. - 13:7(2021), pp. 1-20. [10.15252/emmm.202012872]

miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC

Segatto I.;Rampioni Vinciguerra G. L.;Fanetti G.;Favero A.;Vecchione A.;
2021

Abstract

Radiotherapy (RT) plus the anti-EGFR monoclonal antibody Cetuximab (CTX) is an effective combination therapy for a subset of head and neck squamous cell carcinoma (HNSCC) patients. However, predictive markers of efficacy are missing, resulting in many patients treated with disappointing results and unnecessary toxicities. Here, we report that activation of EGFR upregulates miR-9 expression, which sustains the aggressiveness of HNSCC cells and protects from RT-induced cell death. Mechanistically, by targeting KLF5, miR-9 regulates the expression of the transcription factor Sp1 that, in turn, stimulates tumor growth and confers resistance to RT+CTX in vitro and in vivo. Intriguingly, high miR-9 levels have no effect on the sensitivity of HNSCC cells to cisplatin. In primary HNSCC, miR-9 expression correlated with Sp1 mRNA levels and high miR-9 expression predicted poor prognosis in patients treated with RT+CTX. Overall, we have discovered a new signaling axis linking EGFR activation to Sp1 expression that dictates the response to combination treatments in HNSCC. We propose that miR-9 may represent a valuable biomarker to select which HNSCC patients might benefit from RT+CTX therapy.
2021
egfr inhibitors; hnscc; klf5; radiotherapy; sp1
01 Pubblicazione su rivista::01a Articolo in rivista
miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC / Citron, F.; Segatto, I.; Musco, L.; Pellarin, I.; Rampioni Vinciguerra, G. L.; Franchin, G.; Fanetti, G.; Micciche, F.; Giacomarra, V.; Lupato, V.; Favero, A.; Concina, I.; Srinivasan, S.; Avanzo, M.; Castiglioni, I.; Barzan, L.; Sulfaro, S.; Petrone, G.; Viale, A.; Draetta, G. F.; Vecchione, A.; Belletti, B.; Baldassarre, G.. - In: EMBO MOLECULAR MEDICINE. - ISSN 1757-4676. - 13:7(2021), pp. 1-20. [10.15252/emmm.202012872]
File allegati a questo prodotto
File Dimensione Formato  
Citron_miR-9-modulates_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 6.01 MB
Formato Adobe PDF
6.01 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1560269
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 17
social impact